Nicholas Moore, Ph.D. has been named director of development and pharmacology, discovery R&D, AMRI. Dr. Moore will be responsible for the company's internal R&D portfolio, including the progression of discovery phase programs and the guidance of emerging candidates toward clinical trials. Dr. Moore will report to Bruce Sargent, Ph.D., vice president of discovery R&D.  
   
Dr. Moore has more than 27 years of industrial experience in experimental pharmacology and drug development from early discovery through late clinical phases. Most recently, he was responsible for behavioral pharmacology at Lundbeck Research USA as an associate director in the neuroscience division. Prior to Lundbeck, Dr. Moore spent 23 years in neuroscience discovery research at the Lilly Research Center in roles of increasing responsibility. He has extensive knowledge of preclinical studies, product in-licensing, due diligence and laboratory animal science. While at Lilly he directed the preclinical studies required for the successful development and commercialization of schizophrenia  drug Zyprexa.
   
“Dr. Moore’s skills and experience strengthen our R&D capabilities, helping us build on our existing platform which has already delivered an AMRI oncology compound into Phase I, and in collaboration with BMS, the nomination of two clinical candidates, one of which is currently enrolled into Phase I studies by BMS,” said Dr. Sargent.

News from our sister sites